Seraprevir

Drug Profile

Seraprevir

Alternative Names: GP-205

Latest Information Update: 22 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ginkgo Pharma
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 19 Apr 2017 Efficacy, safety and pharmacokinetics data from a phase I trial in Hepatitis C presented at The International Liver Congress 2017 (ILC-2017)
  • 19 Apr 2017 Ginkgo Pharma completes enrolment in a phase I trial for Hepatitis C in China before April 2017
  • 10 Mar 2016 Ginkgo Pharma has patent protection for seraprevir in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top